AlphaCentric Advisors LLC has acquired a brand new stake in Fulgent Genetics, Inc. (Nasdaq: FLGT – Get the score) within the third quarter, in keeping with the newest 13F submitting with the Securities and Alternate Fee. The fund acquired 30,500 shares of the corporate’s inventory, with an estimated worth of $1,163,000. Fulgent Genetics makes up 1.2% of the holdings of AlphaCentric Advisors LLC, making the inventory the twentieth largest holding. AlphaCentric Advisors LLC owns 0.10% of Fulgent Genetics as of its most up-to-date SEC filings.
→ The Greatest “Lacking Ingredient” within the $7 Trillion EV Market (from funding developments)
Various institutional traders and hedge funds have additionally made modifications to their positions in FLGT. Los Angeles Capital Administration LLC elevated its place in shares of Fulgent Genetics by 74.7% through the second quarter. Los Angeles Capital Administration LLC now owns 19,614 shares of the corporate’s inventory valued at $1,070,000 after buying an extra 8,388 shares final quarter. Victory Capital Administration boosted its place in shares of Fulgent Genetics by 20.6% through the second quarter. Victory Capital Administration now owns 27,514 shares of the corporate’s inventory valued at $1,500,000 after buying an extra 4,693 shares final quarter. Ronald Blue Belief, Inc. elevated its place in shares of Fulgent Genetics by 1,114.0% through the third quarter. The Ronald Blue Belief now owns 607 shares of the corporate’s inventory, valued at $33,000, after buying an extra 557 shares final quarter. The Texas Everlasting Faculties Fund elevated its place in shares of Fulgent Genetics by 2.4% through the third quarter. The Texas Everlasting Faculty Fund now owns 14,587 shares of the corporate’s inventory price $556,000 after buying an extra 339 shares final quarter. Lastly, Pavadi Capital LLC strengthened its place in shares of Fulgent Genetics up 18.9% through the second quarter. Pavadi Capital LLC now owns 81,277 shares of the corporate’s inventory valued at $4,432,000 after buying an extra 12,944 shares final quarter. 43.22% of the shares are at the moment held by hedge funds and different institutional traders.
Wall Road analyst forecasts for progress
A number of analysts have issued reviews on the corporate. Piper Sandler downgraded Fulgent Genetics from an “obese” score to a “impartial” score and lower the corporate’s value goal from $65.00 to $40.00 in a report on Thursday, December eighth. Raymond James lined Fulgent Genetics in a report on Friday, November 18th. They issued a “Superior” score and a value goal of $45.00 for the corporate. StockNews.com Protection of Fulgent Genetics is assumed in a report on Wednesday, October twelfth. They issued a “remark” score for the corporate. Lastly, Credit score Suisse lowered its value goal on Fulgent Genetics from $65.00 to $50.00 and put an “outperform” score on the inventory in a analysis be aware on Monday, November 14th. Two equities analysis analysts have rated the inventory with a maintain score and two have given a purchase score to the inventory. Based on MarketBeat.com, the corporate at the moment has a mean score of “Average Purchase” and a consensus value goal of $45.00.
Gene inventory efficiency
FLGT inventory It traded as excessive as $1.52 throughout mid-day buying and selling on Thursday, to achieve $36.27. The corporate’s buying and selling quantity amounted to 93,338 shares, in comparison with a mean buying and selling quantity of 201,029. The corporate has a market capitalization of $1.07 billion, a price-to-earnings ratio of three.99 and a beta of 1.58. The corporate has a 50-day easy shifting common of $32.74 and a 200-day easy shifting common of $40.10. Register Fulgent Genetics, Inc. The 52-week low is at $28.53 and the 52-week excessive is at $73.47.
Fulgent Genetics (Nasdaq: FLGT – Get the score) final launched its quarterly earnings information on Monday, November seventh. The corporate reported $0.11 earnings per share for the quarter, beating analyst estimates of ($0.02) by $0.13. The corporate had income of $105.66 million for the quarter, in comparison with a consensus estimate of $103.70 million. Fulgent Genetics had a return on fairness of twenty-two.10% and a web margin of 33.82%. As a gaggle, analysts count on Fulgent Genetics, Inc. 4.93 earnings per share for the present yr.
Fulgent Genetics Firm Profile
Fulgent Genetics, Inc. is a expertise firm engaged in offering gene testing and sequencing options. Provides genes and panels, identified mutations, hereditary most cancers, service screening, and tumor diagnostics options. The corporate was integrated on Could 13, 2016 and is headquartered in Temple Metropolis, California.
This prompt information alert was created by MarketBeat’s narrative science and monetary information expertise to offer readers with the quickest, most correct reporting potential. This story was reviewed by the MarketBeat editorial staff previous to publication. Please ship any questions or feedback about this story to email@example.com.
Earlier than you take into account Fulgent Genetics, you may wish to hear this.
MarketBeat tracks Wall Road’s top-rated and top-performing analysis analysts and the shares they suggest to their purchasers every day. Choose MarketBeat file 5 shares That prime analysts are quietly all for their purchasers to purchase now earlier than the broader market catches on…and Fulgent Genetics wasn’t even on the listing.
Whereas Fulgent Genetics at the moment has a “average purchase” score amongst analysts, the higher-rated analysts assume these 5 shares are a greater purchase.